Can We Make Life?
By Nova Wonders,
PBS [Cites CGS' Marcy Darnovsky]
| 05. 23. 2018
"It's alive!" Since Dr. Frankenstein spoke those famous words, we've been alternately enthralled and terrified by the idea of creating life in the lab. Now, a revolution in genetic engineering and thrilling innovations in synthetic biology are bringing that dream—or nightmare, as the case may be—closer to reality. New tools allow researchers to use cells to create their own DNA and edit it into existing genomes with more ease and less cost than ever before. Along with renewed hopes for treating some genetic diseases, there's serious talk of using the newest technologies to bring long-extinct animals back from the dead – like the team hoping to resurrect the woolly mammoth. Science fiction is quickly becoming science fact. Another daring genetic experiment to bioengineer animals could prevent Lyme disease. But the power to make life comes with deep ethical questions. What are the potential rewards—and dangers—of tinkering with nature? NOVA Wonders explores the benefits and the burden of risk surrounding the controversial new technology.
Image via Flickr
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...